The authors concluded that the use of early anticoagulation in patients with acute ischaemic cardioembolic stroke to prevent early recurrence or to improve functional outcome is not supported by the evidence. This was a well-conducted review and the authors' conclusions are likely to be reliable.
To evaluate the efficacy and safety of anticoagulants for the initial treatment of patients with acute cardioembolic stroke.
Searching MEDLINE, EMBASE (both from 1980 to February 2006 and the Cochrane Library (Issue 1, 2006) were searched using the reported search terms. The reference lists of journal articles were screened for additional studies and abstracts from major international meetings were screened for unpublished studies.
Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion in the review.
Specific interventions included in the review
Studies that compared initial treatment (within 48 hours) with anticoagulants (subcutaneous and intravenous unfractionated heparin, subcutaneous low molecular weight heparin, subcutaneous and intravenous heparinoids) with other treatments (placebo or aspirin) were eligible for inclusion. The included studies evaluated unfractionated heparin, low molecular weight heparin (tinzaparin, dalteparin and nadroparin) and a heparinoid (danaparoid). The control treatments were aspirin, placebo and no heparin. Treatment duration ranged from 5 to 14 days. The time interval to treatment ranged from less than 3 hours to less than 48 hours.
Participants included in the review
Studies of patients randomised within 48 hours of an objectively diagnosed stroke of presumed cardioembolic aetiology were eligible for inclusion. Most of the participants in the included studies had atrial fibrillation; there was a variety of cardioembolic sources in the other participants.
Outcomes assessed in the review
Studies that used objective methods to assess death, disability, all strokes, recurrent ischaemic stroke and cerebral symptomatic bleeding were eligible for inclusion. The review assessed a composite outcome of death or disability at final follow-up (at least 3 months), all strokes (ischaemic and haemorrhagic) within 14 days, early recurrent stroke (within 14 days), pulmonary embolism and symptomatic intracranial bleeding.
How were decisions on the relevance of primary studies made? Two reviewers independently selected the studies.
Assessment of study quality
Two reviewers independently assessed validity using the criteria described by Schultz et al.: methods used to generate randomisation sequence; allocation concealment; blinding of the patient and outcome assessor; and completeness of follow-up.
